Interní Med. 2017; 19(1): 42-46 | DOI: 10.36290/int.2017.008

Infliximab

doc. MUDr. Karel Urbánek, Ph.D.
Ústav farmakologie LF UP a FN Olomouc

Infliximab is the first monoclonal antibody directed to TNFα. Used in the treatment of rheumatoid arthritis or other arthritis, inflammatory

bowel diseases and psoriasis. Infliximab is administered by slow intravenous infusion, typically at doses of 3–5 mg / kg

at intervals of 1-8 weeks. It is slowly eliminated from the body with a half-life of 7–12 days. For its high effectiveness and safety is

a targeted first-line treatment of these diseases. Its side effects include especially infusion reactions and the risk of opportunistic

infections, other adverse reactions are generally mild or infrequent.

Keywords: infliximab, pharmacodynamics, pharmacokinetics, clinical use, adverse effects

Published: February 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánek K. Infliximab. Interní Med. 2017;19(1):42-46. doi: 10.36290/int.2017.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet. 1983; 2(8359): 1115-1119. Go to original source... Go to PubMed...
    2. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015; 27(1): 55-62. Go to original source... Go to PubMed...
    3. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993; 36(12): 1681-1690. Go to original source... Go to PubMed...
    4. Bradley JR. TNF-mediated inflammatory dinase. J Pathol. 2008; 214(2): 149-160. Go to original source... Go to PubMed...
    5. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000; 43(1): 38-47. Go to original source...
    6. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2016; 10(8): 989-997. Go to original source... Go to PubMed...
    7. Brunner PM, Koszik F, Reininger B, et al. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan) + dendritic cells and macrophages. J Allergy Clin Immunol. 2013; 132(5): 1184-1193. Go to original source... Go to PubMed...
    8. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007; 46(8): 645-660. Go to original source... Go to PubMed...
    9. Ciferská H, Horák P, Strojil J, Skácelová M. Biologická terapie v revmatologii. Klin Farmakol Farm 2010; 24(4): 197-206.
    10. Elalouf O, Elkayam O. Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag. 2015; 11: 1719-1726. Go to original source...
    11. Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017; 15(1): 25-36.e27. Go to original source... Go to PubMed...
    12. Yang LS, Alex G, Catto-Smith AG. The use of biologic agents in pediatric inflammatory bowel disease. Curr Opin Pediatr. 2012; 24(5): 609-614. Go to original source... Go to PubMed...
    13. Wang J, Zhan Q, Zhang L. A systematic review on the efficacy and safety of Infliximab in patients with psoriasis. Hum Vaccin Immunother. 2016; 12(2): 431-437. Go to original source... Go to PubMed...
    14. Korsten P, Strohmayer K, Baughman RP, Sweiss NJ. Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. Clin Pulm Med. 2016; 23(2): 67-75. Go to original source... Go to PubMed...
    15. Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016; 174(5): 970-978. Go to original source... Go to PubMed...
    16. Schwartzman S. Advancements in the management of uveitis. Best Pract Res Clin Rheumatol. 2016; 30(2): 304-315. Go to original source... Go to PubMed...
    17. Zhu FH, Ang JY. The Clinical Diagnosis and Management of Kawasaki Disease: a Review and Update. Curr Infect Dis Rep. 2016; 18(10): 32. Go to original source... Go to PubMed...
    18. Weber-Schoendorfer C, Oppermann M, el al. Pregnancy outcome after TNF-? inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015; 80(4): 727-739. Go to original source... Go to PubMed...
    19. Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med. 2016; 12(3): 1693-1704. Go to original source... Go to PubMed...
    20. Chen Y, Sun J, Yang Y, Huang Y, Liu G. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses. Clin Rheumatol. 2016; 35(1): 1-18. Go to original source... Go to PubMed...
    21. D'Haens G, Reinisch W, Colombel JF, et al. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade(R)] or Conventional Therapy.
    22. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009; 301(1): 99-105. Go to original source... Go to PubMed...
    23. Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs. 2015; 29(4): 241-58. Go to original source... Go to PubMed...
    24. Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol. 2011; 65(4): 870. Go to original source... Go to PubMed...
    25. Urbánek K. První biosimilární monoklonální protilátka - infliximab. Klin Farmakol Farm 2014; 28(1): 19-22.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.